Pacira (CH:82P)
NASDAQ:82P
82P Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Improved Balance Sheet And Low LeveragePacira’s materially reduced debt and improved debt-to-equity profile increase financial resilience and strategic optionality. A stronger balance sheet supports sustained R&D and commercial investment, funds share repurchases, and provides a buffer against clinical or reimbursement setbacks over the next 2–6 months.
Consistent Operating And Free Cash Flow GenerationConsistent positive operating and free cash flow gives Pacira the ability to self-fund growth initiatives, meet near-term development milestones and execute buybacks without reliance on external financing. Even with recent softening, steady cash generation underpins durable capital allocation flexibility.
Durable EXPAREL Franchise Supported By IP And CoverageA broadened patent estate plus expanded reimbursement (110M+ covered lives noted elsewhere) strengthens EXAPAREL’s defensive moat versus generics and supports sustained hospital and outpatient adoption. This structural protection and payer recognition underpin multi-quarter revenue visibility for the core product.
Bears Say
Volatile Profitability And Thin MarginsEarnings volatility and currently thin operating/net margins limit predictability of sustained earnings power. This inconsistency lowers returns on equity, complicates long-term forecasting, and raises execution risk for funding both commercialization and development without eroding margins or relying on constant cost reductions.
Revenue Mix And GPO Discounting PressureShifts toward lower‑priced vial mix and third‑party GPO discounting compress reported revenue versus volume growth. Persistent channel discounts can erode ASPs and margins, making top-line growth less durable unless pricing, mix or payer contracts are renegotiated to protect realized revenue per procedure.
Reimbursement Policy Risk (NOPAIN Expiration)Medicare’s NOPAIN-driven reimbursement outside the surgical bundle materially supports EXPAREL adoption. Its scheduled 2027 expiration creates a structural revenue risk: withdrawal or change in policy could reduce payer access and utilization, materially affecting medium-term procedure economics and growth assumptions.
Pacira Pharmaceuticals News
82P FAQ
What was Pacira’s price range in the past 12 months?
Currently, no data Available
What is Pacira’s market cap?
Pacira’s market cap is CHF723.49M.
When is Pacira’s upcoming earnings report date?
Pacira’s upcoming earnings report date is Aug 04, 2026 which is in 41 days.
How were Pacira’s earnings last quarter?
Pacira released its earnings results on Apr 30, 2026. The company reported $0.478 earnings per share for the quarter, beating the consensus estimate of $0.437 by $0.041.
Is Pacira overvalued?
According to Wall Street analysts Pacira’s price is currently Undervalued.
Does Pacira pay dividends?
Pacira does not currently pay dividends.
What is Pacira’s EPS estimate?
Pacira’s EPS estimate is 0.52.
How many shares outstanding does Pacira have?
Currently, no data Available
What happened to Pacira’s price movement after its last earnings report?
Pacira reported an EPS of $0.478 in its last earnings report, beating expectations of $0.437. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Pacira?
Currently, no hedge funds are holding shares in CH:82P
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pacira Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.27%
12-Months-Change
Fundamentals
Return on Equity
0.73%
Trailing 12-Months
Asset Growth
-23.83%
Trailing 12-Months
Company Description
Pacira
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.
82P Company Deck
82P Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominately positive picture: the company reported solid top-line momentum across core products (EXPAREL, ZILRETTA, ioverao) with meaningful YoY growth, strengthened IP protection, expanded reimbursement coverage (110M+ covered lives), encouraging pipeline progress with near-term readouts, and healthy adjusted EBITDA and buyback activity. Near-term challenges include revenue mix impacts from a new GPO and winter storms, modest margin compression and elevated SG&A/R&D spending tied to strategic initiatives, and policy timing risk around NOPAIN’s scheduled 2027 expiration. On balance the positives — sustainable product growth, strengthened commercial and IP positions, active pipeline catalysts, and disciplined capital returns — outweigh the lowlights.View all CH:82P earnings summaries82P Stock 12 Month Forecast
Average Price Target
$23.95
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Collegium Pharmaceutical
―
Options Prices
Currently, No data available
---